Efgartigimod PH20 SC

ApprovedActive

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Chronic Inflammatory Demyelinating Polyneuropathy

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Trial Timeline

Dec 10, 2024 → Feb 23, 2026

NCT ID

NCT06637072

About Efgartigimod PH20 SC

Efgartigimod PH20 SC is a approved stage product being developed by Argenx for Chronic Inflammatory Demyelinating Polyneuropathy. The current trial status is active. This product is registered under clinical trial identifier NCT06637072. Target conditions include Chronic Inflammatory Demyelinating Polyneuropathy.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Inflammatory Demyelinating Polyneuropathy were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07264426	Pre-clinical	Recruiting	Aug 11, 2025	Oct 1, 2029	Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT06909214	Approved	Recruiting	Apr 17, 2025	May 1, 2027	New Onset Generalized Myasthenia Gravis (gMG)
NCT06684847	Phase 3	Recruiting	Jan 15, 2025	Jul 1, 2028	Primary Sjogrens Disease
NCT06637072	Approved	Active	Dec 10, 2024	Feb 23, 2026	Chronic Inflammatory Demyelinating Polyneuropathy
NCT06392386	Phase 2/3	Recruiting	Jun 28, 2024	Sep 30, 2026	Generalized Myasthenia Gravis
NCT05979441	Phase 3	Recruiting	Sep 12, 2023	Sep 1, 2028	Myositis
NCT04812925	Phase 3	Active	Nov 17, 2021	Oct 1, 2026	Primary Immune Thrombocytopenia
NCT04818671	Phase 3	Completed	Apr 26, 2021	Dec 31, 2024	Generalized Myasthenia Gravis
NCT04687072	Phase 3	Completed	Dec 16, 2020	Oct 9, 2023	Primary Immune Thrombocytopenia
NCT04280718	Phase 2	Active	Sep 18, 2020	Apr 30, 2027	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Competing Products

20 competing products in Chronic Inflammatory Demyelinating Polyneuropathy

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25